Early identification and prevention of acute compartment syndrome using a novel electrical impedance-based muscle-monitoring device

使用新型电阻抗肌肉监测装置早期识别和预防急性筋膜室综合征

基本信息

  • 批准号:
    10490448
  • 负责人:
  • 金额:
    $ 98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Acute compartment syndrome (ACS) remains one of the most devastating and readily overlooked traumatic musculoskeletal disorders in clinical practice. In this condition, pressure increases in one of the body’s space-limited compartments, due to direct trauma or bone fracture, resulting in injury to all of the compartment’s contents, including muscle and nerve. Once full-blown ACS develops, the consequences are uniformly catastrophic, with permanent tissue destruction, sometimes necessitating amputation. If caught early, procedures can be used to save the limb. A non-invasive technology that can monitor for the development of the condition both in and out of the hospital and even with the patient’s having a cast in place could serve a critical purpose for ACS prevention. One approach that holds substantial potential for this purpose is electrical impedance myography (EIM). In EIM, a weak electrical current is applied to a muscle or group of muscle and the consequent surface voltages measured, providing an index of myofiber health. Previous studies of impedance techniques have demonstrated high sensitivity to tissue ischemia and injury, including intracellular edema and reductions in extracellular space. Thus, we hypothesize that the application of EIM to muscle could serve as a sensitive method for assessing the onset of ACS. Myolex Inc, a Boston-based small business, has as its main interest the design and development of EIM technology for broad medical use. The company in conjunction with Beth Israel Deaconess Medical Center has studied the specific application of EIM technology for the assessment of ACS in a well-established rat model of this disorder. Data collected and analyses completed previously have demonstrated the sensitivity of EIM to the development of ACS. In this Phase 2 SBIR, we plan to extend the success of our early investigations by developing a self-contained, wireless, battery-powered, wearable ACS detector that can even work on a casted limb that we have called the Myolex® mAlertTM. In Specific Aim 1, building upon an already functioning early prototype, we will create a system, that can be placed on a person at risk for ACS to assess the development of the condition. The system will be wireless and small such that it can be applied prior to cast placement and be easily removable once the period of concern has passed. We will test basic functionality in a small group of healthy subjects. In Specific Aim 2, we will apply this system in a porcine model of ACS while simultaneously measuring tissue perfusion pressures and also preforming measurement on the contralateral limb. We anticipate showing the mAlert’s sensitivity to progressing muscle injury and to its improvement after fasciotomy. At the conclusion of this work, Myolex will be well-positioned to test the device in human subjects at risk for developing ACS and achieve ultimate FDA approval.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David P. Dickinson其他文献

David P. Dickinson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10685312
  • 财政年份:
    2021
  • 资助金额:
    $ 98万
  • 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10490872
  • 财政年份:
    2021
  • 资助金额:
    $ 98万
  • 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10345963
  • 财政年份:
    2021
  • 资助金额:
    $ 98万
  • 项目类别:
Development of Highly Functionalized Serum Albumins as Boron Delivery Carries to Tumor for Neutron Capture Therapy
开发高功能化血清白蛋白作为硼输送至肿瘤以进行中子捕获治疗
  • 批准号:
    17H02202
  • 财政年份:
    2017
  • 资助金额:
    $ 98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Studies on Asymmetric Nitroaldol Reaction using mutant albumins
突变体白蛋白不对称硝醛醇反应的研究
  • 批准号:
    16K05706
  • 财政年份:
    2016
  • 资助金额:
    $ 98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SPIN LABELING STUDIES OF NORMAL RECOMBINANT & MUTANT HUMAN SERUM ALBUMINS
正常重组的旋转标记研究
  • 批准号:
    6118869
  • 财政年份:
    1999
  • 资助金额:
    $ 98万
  • 项目类别:
COPPER BINDING OF COMMERCIAL, NORMAL RECOMBINANT, & MUTANT HUMAN SERUM ALBUMINS
商业、正常重组的铜结合,
  • 批准号:
    6118864
  • 财政年份:
    1999
  • 资助金额:
    $ 98万
  • 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia in Fowl
家禽双清蛋白血症血清白蛋白的结构与代谢特征
  • 批准号:
    67B6472
  • 财政年份:
    1967
  • 资助金额:
    $ 98万
  • 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia
双清蛋白血症血清白蛋白的结构和代谢特征
  • 批准号:
    65B3344
  • 财政年份:
    1965
  • 资助金额:
    $ 98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了